NCT01211275 - Standard Chemotherapy With of Without Axitinib in Malignant Mesothelioma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 22, 2009

Primary Completion Date

November 13, 2012

Study Completion Date

May 6, 2013

Conditions

Malignant Pleural Mesothelioma

Interventions

BIOLOGICAL

axitinib

axitinib: 5 mg BID, day 2 until day 21 of each cycle; cisplatin: 75 mg/m2 day 1, every 3 weeks; pemetrexed: 500 mg/m2 day 1, every 3 weeks.

DRUG

chemotherapy

cisplatin: 75 mg/m2 day 1, every 3 weeks; pemetrexed: 500 mg/m2 day 1, every 3 weeks.

Trial Locations (1)

Antoni van Leeuwenhoekziekenhuis (NKI-AVL), Amsterdam